POELLATH advises the management of Aenova Group on sale to Kühne Holding AG
Kühne Holding AG has acquired a majority stake in Aenova Group (“Aenova”), worldwide leading contract manufacturer and development provider for the pharmaceutical and healthcare industry. The seller is the private equity firm BC Partners, which remains on board as a minority shareholder and will reinvest alongside Kühne Holding AG as part of the transaction. The parties have agreed not to disclose the financial details. The closing of the transaction is still subject to the usual regulatory approvals.
POELLATH acted as legal advisor to the management of Aenova Group in connection with the sale regarding the management participation.
Aenova, based in Starnberg near Munich, is a full-service provider for the development, manufacture and packaging of all common dosage forms, product groups and active ingredient classes of pharmaceuticals and dietary supplements for human and animal health. The company employs around 4,000 people at 14 production sites in Europe and the USA. With BC Partners as its owner, Aenova has developed into one of the ten largest CDMOs (contract development and manufacturing organizations) in the world.
Kühne Holding AG unites the entrepreneurial interests of Klaus-Michael Kühne. With an entrepreneurial focus, it holds a majority stake in Kühne+Nagel International AG and is the largest single shareholder of Hapag-Lloyd AG, Deutsche Lufthansa AG and Brenntag SE.
POELLATH advised the management of Aenova Group in connection with the sale regarding the management participation with the following Munich team:
- Dr. Benedikt Hohaus (partner, management participations)
- Silke Simmer (counsel, management participations)
- Jan Lukas Jungclaus (associate, management participations)
